VITA 34 AG Share Price London S.E.

Equities

0NLV

DE000A0BL849

Healthcare Facilities & Services

Market Closed - London S.E. 01:34:41 11/01/2021 pm IST 5-day change 1st Jan Change
12.6 EUR -0.40% Intraday chart for VITA 34 AG +186.35% +186.35%

Financials

Sales 2024 * 8.1Cr 8.76Cr 731.38Cr Sales 2025 * 8.34Cr 9.02Cr 753.05Cr Capitalization 8.47Cr 9.16Cr 764.95Cr
Net income 2024 * -10L -10.81L -9.03Cr Net income 2025 * - 0 0 EV / Sales 2024 * 1.04 x
Net cash position 2024 * 2L 2L 1.81Cr Net cash position 2025 * 73L 78.92L 66Cr EV / Sales 2025 * 0.93 x
P/E ratio 2024 *
-60.8 x
P/E ratio 2025 *
-243 x
Employees 758
Yield 2024 *
-
Yield 2025 *
-
Free-Float 30.42%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.40%
1 week+186.35%
Current month+186.35%
1 month+186.35%
3 months+186.35%
6 months+186.35%
Current year+186.35%
More quotes
1 year
3.92
Extreme 3.92
12.60
3 years
3.92
Extreme 3.92
16.49
5 years
3.92
Extreme 3.92
17.04
10 years
3.88
Extreme 3.875
17.04
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 22/22/22
Director of Finance/CFO - 01/22/01
Investor Relations Contact - -
Members of the board TitleAgeSince
Director/Board Member 49 01/20/01
Chairman 59 15/21/15
Director/Board Member 51 -
More insiders
Vita 34 International AG is a Germany-based company engaged in the medical technology sector. The Company is involved in the long-term storage and processing of stem cells from human umbilical cord blood. The cells are collected at the child’s birth and can be used later in his or her life for the treatment of many diseases, such as anemia, diabetes, degenerative joint diseases, cancer, neurological deficits after brain injuries, cartilage damages and others. They also allow the growing of whole organs, such as the liver. On average, one out seven individuals, whose cells are stored, receives autologous stem cell transplant by the age of 70. The Company acts as a cord blood bank and is also engaged in research activities in the area of regenerative medicine, including curing the consequences of strokes and heart attacks. The Company operates in Germany, Spain and Denmark.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
4.86 EUR
Average target price
6 EUR
Spread / Average Target
+23.46%
Consensus

Annual profits - Rate of surprise